Hence, these data suggest an evolutionary model where loss of whole chromosome 9 is selected as a driver event early in tumor evolution (e.g., due to CDKN2A), but then later leads to collateral sensitivity (Zhao et al., 2016) to immunotherapy, possibly due to 9q34 (TRAF2) loss. This evidence concerns the gene CDKN2A and neoplasm.